Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Apoptosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    166 result(s) found for: Apoptosis. Displaying page 8 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2006-001907-13 Sponsor Protocol Number: LAP107692 Start Date*: 2005-12-21
    Sponsor Name:GLAXO SMITH KLINE RESEARCH DEVELOPMENT LTD
    Full Title: LETROZOLE versus LETROZOLE PLUS LAPATINIB GW572016 IN HORMONE-SENSITIVE, HER-2 NEGATIVE OPERABLE BREAST CANCER. A DOUBLE BLIND RANDOMIZED PHASE II STUDY WITH BIOMARKER EVALUATION
    Medical condition: Primary breast cancer hormone-sensitive in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057654 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005933-12 Sponsor Protocol Number: E7080-G000-201 Start Date*: 2009-10-29
    Sponsor Name:Eisai Limited
    Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified...
    Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003044-53 Sponsor Protocol Number: B1271003 Start Date*: 2012-01-30
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US
    Full Title: AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER
    Medical condition: ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER WITH KI-67 HIGHER THAN 10% AND ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE ADVANCED BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003176-21 Sponsor Protocol Number: TRIO 017 Start Date*: 2008-12-31
    Sponsor Name:Cancer International Research Group
    Full Title: A phase II, open label multicenter trial of panobinostat (LBH589) monotherapy in women with HER2 negative locally recurrent or metastatic breast cancer
    Medical condition: Women with HER-2 negative locally recurrent or metastatic breast cancer;
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) BE (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004909-33 Sponsor Protocol Number: LCTU122 Start Date*: 2015-09-21
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: Thrombin Inhibition Preoperatively in Early Breast Cancer
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-000864-94 Sponsor Protocol Number: EORTC protocol 10054 Start Date*: 2007-01-15
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A phase I-II study of lapatinib and docetaxel as neoadjuvant treatment for HER-2 positive locally advanced/inflammatory or large operable breast cancer.
    Medical condition: Locally advanced/inflammatory or large operable brest cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2007-002552-42 Sponsor Protocol Number: CBGT226A2101 Start Date*: 2008-01-18
    Sponsor Name:Novartis Farmacéutica, S.A
    Full Title: Estudio de fase I/II, multicéntrico, abierto de BGT226, administrado por vía oral a pacientes adultos con tumores sólidos avanzados, incluyendo pacientes con cáncer de mama avanzado
    Medical condition: Escalado de dosis: Tumores sólidos avanzados Fase de expansión: Cancer de mama avanzado
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001813-17 Sponsor Protocol Number: R1282 Start Date*: 2012-08-06
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: Study of apoptosis related changes and endothelial responses of multiple myeloma patients treated with chemotherapy.
    Medical condition: Chemotherapy related thrombosis in patients treated for multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021182 Iatrogenic pulmonary embolism and infarction LLT
    14.1 10047065 - Vascular disorders 10013878 DVT of calf LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069909 Metastatic pulmonary embolism PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10000853 Acute massive pulmonary embolism LLT
    14.1 10047065 - Vascular disorders 10013877 DVT LLT
    14.1 10047065 - Vascular disorders 10013879 DVT of legs LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003833-25 Sponsor Protocol Number: EFACLE2008 Start Date*: 2009-02-05
    Sponsor Name:Universitätskrankenhaus Schleswig-Holstein
    Full Title: Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study
    Medical condition: Cutaneous lupus erythematosus (discoid LE or subacute cutaneous LE) or systemic lupus erythematosus with cutaneous DLE or SCLE lesions without major organ involvment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013071 Discoid lupus erythematosis LLT
    9.1 10057903 Subacute cutaneous lupus erythematosus LLT
    9.1 10056509 Cutaneous lupus erythematosus LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001379-29 Sponsor Protocol Number: HCL-PG02 Start Date*: 2014-07-04
    Sponsor Name:Dipartimento di Medicina
    Full Title: A PHASE II OPEN LABEL SINGLE CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR DABRAFENIB (TAFINLAR) IN PREVIOUSLY TREATED PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) CARRYING...
    Medical condition: Hairy cell leukemia (HCL)carrying the BRAF-V600E mutation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019053 Hairy cell leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000172-38 Sponsor Protocol Number: NP137-CT-02 Start Date*: 2020-09-04
    Sponsor Name:NETRIS PHARMA
    Full Title: A randomised, multicentre, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological activity (Phase II) of a humanized monoclonal antibody targeting Ne...
    Medical condition: Locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001197 Adenocarcinoma of the cervix PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014987 Epidermoid carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003497-48 Sponsor Protocol Number: EMPATHY Start Date*: 2021-11-29
    Sponsor Name:Medical University of Warsaw
    Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial
    Medical condition: acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001462-17 Sponsor Protocol Number: WSG-AM06 Start Date*: 2012-03-29
    Sponsor Name:Westdeutsche Studiengruppe GmbH
    Full Title: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
    Medical condition: Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005276-14 Sponsor Protocol Number: RGCH004 Start Date*: 2016-06-03
    Sponsor Name:Sykehuset Østfold HF
    Full Title: Prolonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial.
    Medical condition: Immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003832-30 Sponsor Protocol Number: 11-PIR-11 Start Date*: 2012-06-21
    Sponsor Name:Nektar Therapeutics
    Full Title: The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Locally Recurr...
    Medical condition: Locally Recurrent Breast Cancer, Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015407-47 Sponsor Protocol Number: CAUY922A2202 Start Date*: 2010-10-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy
    Medical condition: Patients with advanced gastric cancer who have progressed after one line of chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001186-20 Sponsor Protocol Number: GEIS-83 Start Date*: 2021-10-22
    Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS
    Full Title: Phase Ib/II multicohort trial of different schemes of PM14 in monotherapy and in combination with radiotherapy in soft tissue sarcomas and other solid tumors
    Medical condition: Advanced soft tissue sarcoma and other solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003408-65 Sponsor Protocol Number: Start Date*: 2016-08-26
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
    Medical condition: Heavy menstrual bleeding
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046784 Uterine fibroids LLT
    18.0 10038604 - Reproductive system and breast disorders 10027313 Menorrhagia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-002468-18 Sponsor Protocol Number: EZH-102 Start Date*: 2016-02-19
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
    Medical condition: Atypical teratoid rhabdoid tumor (ATRT), Malignant rhabdoid tumor (MRT), Rhabdoid tumor of kidney (RTK), selected tumors with rhabdoid features. Epithelioid sarcoma, Epithelioid malignant peripher...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064886 Renal medullary carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065870 Atypical teratoid/rhabdoid tumor of CNS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073134 Extraskeletal myxoid chondrosarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073335 Rhabdoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074121 Rhabdoid tumor of the kidney LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003596-17 Sponsor Protocol Number: CMAS825D12201 Start Date*: 2021-03-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A three-period multicenter study, with a randomized withdrawal, double-blinded, placebo-controlled design in Period 2 to evaluate the clinical efficacy, safety and tolerability of MAS825 in NLRC4-G...
    Medical condition: NLRC4-GOF, AIFEC (autoinflammation with infantile enterocolitis)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10084306 Autoinflammation with infantile enterocolitis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 01:39:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA